Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
399 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 | 17 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02835833 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | completed | Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01778933 |
| Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17) |
| completed |
| Early Phase 1 |
| 10 |
| University of PennsylvaniaOTHER |
| 1 |
| Jul 3, 2018 |
| clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | terminated | Phase 2 | 2 | Argos TherapeuticsINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT03052504 | Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy | completed | — | 156 | Jørgen Bjerggaard JensenOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population | terminated | Phase 2 | 13 | vghtpe userOTHER_GOV | 1 | Jun 26, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma(ADAPT) | terminated | Phase 3 | 462 | Argos TherapeuticsINDUSTRY | 8 | Jun 14, 2018 | clinicaltrials |
| NCT00729053 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | completed | Phase 2 | 92 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01411423 | Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan | completed | — | 3,305 | BayerINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01412671 | Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program | completed | — | 117 | BayerINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01829841 | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer | completed | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 3, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02282579 | Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy(SPAZO) | completed | — | 300 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT02747173 | Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques(METHEOS) | terminated | — | 4 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT03091465 | Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib(Spazo-2) | completed | — | 530 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT00529802 | Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer | completed | Phase 2 | 60 | University of ChicagoOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01361113 | Neoadjuvant Pazopanib in Renal Cell Carcinoma | completed | Phase 2 | 21 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02216890 | Safety Study of SGN-CD70A in Cancer Patients | completed | Phase 1 | 38 | Seagen Inc.INDUSTRY | 1 | Apr 19, 2018 | clinicaltrials |
| NCT00923130 | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03471897 | Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma | completed | — | 237 | Chalmers University of TechnologyOTHER | 0 | Apr 17, 2018 | clinicaltrials |
| NCT01107509 | Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers | completed | N/A | 20 | St. Joseph's Healthcare HamiltonOTHER | 1 | Apr 4, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | terminated | Phase 2 | 18 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00448721 | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer | completed | Phase 2 | 24 | AEterna ZentarisINDUSTRY | 1 | Mar 1, 2018 | clinicaltrials |
| NCT02075658 | A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation | completed | N/A | 60 | University of California, IrvineOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01982097 | Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma(SANE) | completed | — | 61 | BayerINDUSTRY | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)(ORCHIDEE) | terminated | Phase 4 | 31 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00782275 | Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 41 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 24, 2018 | clinicaltrials |
| NCT01108445 | Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma(ASPEN) | completed | Phase 2 | 131 | Duke UniversityOTHER | 3 | Jan 16, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | withdrawn | Phase 3 | 0 | Heidelberg Pharma AGINDUSTRY | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02370342 | Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT00726323 | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) | completed | Phase 2 | 74 | GlaxoSmithKlineINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT00979329 | Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST | completed | — | 100 | Radboud University Medical CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00408902 | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | terminated | Phase 2 | 16 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients | completed | Phase 1 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00363194 | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00478725 | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 | completed | Phase 1 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | terminated | Phase 1 | 26 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00278395 | Vorinostat in Treating Patients With Kidney Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | completed | Phase 1 | 2 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01266837 | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)(MARC-2) | completed | Phase 4 | 64 | iOMEDICO AGINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00401583 | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | completed | Phase 1 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 26, 2018source: clinicaltrials